Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk Myelodysplastic syndrome (MDS): Update including extended treatment

被引：51

作者：

Kantarjian, Hagop ^{[1
]}

Fenaux, Pierre ^{[2
]}

Sekeres, Milckael A. ^{[3
]}

Becker, Pamela ^{[4
]}

Boruchov, Adam ^{[5
]}

Bowen, David ^{[6
]}

Larson, Richard ^{[7
]}

Lyons, Roger ^{[8
]}

Muus, Petra ^{[9
]}

Shammo, Jamile ^{[10
]}

Ehrman, Michael ^{[11
]}

Hu, Kuolung ^{[11
]}

Nichol, Janet ^{[11
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Paris 13, Hop Avicenne, Bobigny, France

[3] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA

[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Leeds Teaching Hosp, Leeds, W Yorkshire, England

[7] Univ Chicago, Chicago, IL 60637 USA

[8] Canc Care Ctr S Texas US Oncol, San Antonio, TX USA

[9] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[10] Rush Univ, Med Ctr, Chicago, IL USA

[11] Amgen Inc, Thousand Oaks, CA USA

来源：

关键词：

D O I：

10.1182/blood.V110.11.817.817

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

250

引用

页码：81A / 81A

页数：1